Genomic Health Newswire (Page 3)

Genomic Health Newswire (Page 3)

Comprehensive Real-Time News Feed for Genomic Health. (Page 3)

Results 41 - 60 of 639 in Genomic Health

  1. Genomic Health, Inc. (GHDX) Position Increased by Goldman Sachs Group Inc.Read the original story w/Photo

    Oct 18, 2017 | IntersportsWire

    Goldman Sachs Group Inc. boosted its stake in Genomic Health, Inc. by 26.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission . The institutional investor owned 370,806 shares of the medical research company's stock after buying an additional 76,758 shares during the quarter.

    Comment?

  2. Financial Analysis: Genomic Health (GHDX) & Its PeersRead the original story w/Photo

    Oct 17, 2017 | AmericanBankingNews.com

    Genomic Health is one of 197 publicly-traded companies in the "Biotechnology & Medical Research" industry, but how does it contrast to its peers? We will compare Genomic Health to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings. Genomic Health has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

    Comment?

  3. Zacks Investment Research Upgrades Genomic Health, Inc. (GHDX) to HoldRead the original story w/Photo

    Oct 15, 2017 | IntersportsWire

    According to Zacks, "Genomic Health continues to experience strong growth in its cancer scores. Moreover, the company recently announced expanded Medicare coverage of the Oncotype DX Genomic Prostate Score test.

    Comment?

  4. Genomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from BrokeragesRead the original story w/Photo

    Oct 15, 2017 | IntersportsWire

    Genomic Health, Inc. has earned an average rating of "Hold" from the ten research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and one has given a buy recommendation to the company.

    Comment?

  5. Genomic Health, Inc. (GHDX) COO Sells $159,650.00 in StockRead the original story w/Photo

    Oct 14, 2017 | Daily Political

    Genomic Health, Inc. COO G Bradley Cole sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00.

    Comment?

  6. Genomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment ResearchRead the original story w/Photo

    Oct 13, 2017 | AmericanBankingNews.com

    According to Zacks, "Genomic Health continues to experience strong growth in its cancer scores. Moreover, the company recently announced expanded Medicare coverage of the Oncotype DX Genomic Prostate Score test.

    Comment?

  7. Epic Sciences Release: Liquid Biopsy Test Identifies Androgen...Read the original story

    Oct 12, 2017 | BioSpace

    ... that the best treatment path can be chosen at every clinical decision point. Epic Sciences has partnered with Genomic Health to commercialize the Oncotype DXA AR-V7 Nucleus Detect test, which helps with therapeutic decisions between taxane ...

    Comment?

  8. See the column...Read the original story

    Oct 10, 2017 | Window on the Clearwater

    ... survival. The scientists explored the ability of a diagnostic gene test, the Oncotype DX Recurrence Score (Genomic Health, Inc.), to predict which women could safely avoid receiving chemotherapy. The test had previously been found, using ...

    Comment?

  9. FMI Predicts Global Liquid Biopsy Market Will Reach CAGR of 21.7% During 2016-2026Read the original story w/Photo

    Oct 9, 2017 | SBWire

    ... institutes, and diagnostic centres. Some of the key players in the global liquid biopsy market include Genomic Health, Inc., Biocept, Qiagen, Inc., Trovagene, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and ...

    Comment?

  10. Zacks Investment Research Lowers Genomic Health, Inc. (GHDX) to SellRead the original story w/Photo

    Oct 8, 2017 | AmericanBankingNews.com

    According to Zacks, "Over the past three months, Genomic Health has been trading below the broader industry. Also, the company exited the last reported quarter with wider-than-expected loss.

    Comment?

  11. Genomic Health, Inc. (GHDX) Holdings Lifted by Nordea Investment Management ABRead the original story w/Photo

    Oct 5, 2017 | Daily Political

    Nordea Investment Management AB raised its stake in shares of Genomic Health, Inc. by 8.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,025 shares of the medical research company's stock after buying an additional 4,418 shares during the quarter.

    Comment?

  12. Specialised Therapeutics Group Release: Federal Government Rejects...Read the original story

    Oct 3, 2017 | BioSpace

    ... the test soon after surgery and before commencing follow up treatment. The Oncotype DX test was developed by Genomic Health, Inc. (NASDAQ: GHDX) a world leading provider of genomic-based diagnostic tests that optimise treatment for early stage ...

    Comment?

  13. Genomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord GenuityRead the original story w/Photo

    Oct 1, 2017 | AmericanBankingNews.com

    ... research reports. Jefferies Group LLC restated a "hold" rating and set a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. Zacks Investment Research cut shares of Genomic Health from a "hold" rating to a "sell" ...

    Comment?

  14. Contrasting Inovio PharmaceuticalsRead the original story w/Photo

    Sep 30, 2017 | Daily Political

    Inovio Pharmaceuticals and Genomic Health are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. 24.8% of Inovio Pharmaceuticals shares are owned by institutional investors.

    Comment?

  15. Canaccord Genuity Reaffirms "Buy" Rating for Genomic Health, Inc.Read the original story w/Photo

    Sep 30, 2017 | Daily Political

    ... company's stock. A number of other analysts have also recently issued reports on GHDX. BidaskClub raised Genomic Health from a sell rating to a hold rating in a research report on Saturday, August 26th. Piper Jaffray Companies reaffirmed a hold ...

    Comment?

  16. Contrasting Genomic HealthRead the original story w/Photo

    Sep 28, 2017 | AmericanBankingNews.com

    Genomic Health and Inovio Pharmaceuticals are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Genomic Health has higher revenue and earnings than Inovio Pharmaceuticals.

    Comment?

  17. Cancer Diagnostics Market to Grow at CAGR of 12% by 2022Read the original story w/Photo

    Sep 28, 2017 | SBWire

    Market Research Future adds new report of "Cancer Diagnostics Market Research Report - Global Forecast to 2022" it contains Company information, geographical data and Table of Content Competitive Analysis: Some of the key players in this market are: - Cancer Diagnostics Inc. - Myriad Genetics - Cancer Genetics Inc. - Inspirata - Genomic Health Inc. - MEDITE Cancer Diagnostics Inc. - MDxHealth - Biotheranostics - Pacific Edge - Ventana Medical Systems Inc. - BioMark Diagnostics Inc. - 20/20 GeneSystems Inc. - Provista Diagnostics Inc. - Armune BioScience - Arquer Diagnostics Ltd - Oncimmune Limited - MetaCell Get a Sample Report @ Market Segments: Global cancer diagnostics market has been segmented - On the basis of Type which comprises of biopsy based, endoscopy based, imaging procedure, tumor biomarkers - On the basis of ... (more)

    Comment?

  18. Genomic Health, Inc. (GHDX) Receives "Buy" Rating from Canaccord GenuityRead the original story w/Photo

    Sep 26, 2017 | IntersportsWire

    ... research reports. Jefferies Group LLC reaffirmed a "hold" rating and set a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Cowen and Company reaffirmed a "hold" rating and set a $34.00 price target ...

    Comment?

  19. Genomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from AnalystsRead the original story w/Photo

    Sep 25, 2017 | Daily Political

    Genomic Health, Inc. has been given a consensus rating of "Hold" by the ten ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company.

    Comment?

  20. Lab services companies' shares are getting slammed by Medicare reimbursement cutsRead the original story w/Photo

    Sep 25, 2017 | MarketWatch

    ... impact 'mom and pop' small labs that lack scale," Massaro said, allowing companies like LabCorp, Quest and Genomic Health "to consolidate weaker players." Companies are expected to appeal the proposed rates, especially Quest and LabCorp, both of ...

    Comment?